Une candidature complète en une minute
Un CV et une lettre de motivation personnalisés, prêts à envoyer.
Revolution Medicines seeks a Vice President, Early Discovery Chemistry to lead the science and organization for Early Discovery Chemistry and report to the Senior Vice President of Medicinal Chemistry. You will drive strategy, coordinate across discovery teams, and set the direction for novel chemical matter in oncology.
This executive will foster innovation, expand chemical space using AI/ML, automation, and modern screening, and build a high-performing team with budget and talent development
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.
The Vice President, Early Discovery Chemistry will report to the Senior Vice President of Medicinal Chemistry and Screening Platform Technologies and serve as the scientific and organizational leader for Revolution Medicines' Early Discovery Chemistry organization. The role will lead multidisciplinary teams spanning Early Discovery Chemistry, Analytical Chemistry, library sciences, and enabling discovery technologies to drive the identification of novel chemical matter for Revolution Medicines' oncology pipeline.This executive will define and execute the strategy for discovering high-value chemical matter against challenging targets by integrating innovative chemistry, computational design, AI/ML, automation, and modern screening technologies. The organization will expand accessible chemical space, accelerating hit identification, and delivering differentiated chemical matter into Medicinal Chemistry for lead optimization.The successful candidate will establish Early Discovery Chemistry as a center of scientific excellence that continuously advances technologies, capabilities, and workflows to improve the speed, quality, and probability of success of drug discovery across the Revolution Medicines portfolio.